David M Hockenberry

Title: David M Hockenberry: Innovator in Apoptosis Modulation

Introduction

David M Hockenberry is a notable inventor based in Seattle, WA. He has made significant contributions to the field of cellular biology, particularly in the modulation of apoptosis. His work focuses on developing agents that can influence the apoptotic state of cells, which is crucial for various therapeutic applications.

Latest Patents

Hockenberry holds a patent titled "Compositions and methods for modulating apoptosis in cells over-expressing Bcl-2 family member proteins." This invention provides agents and compositions designed to modulate the apoptotic state of a cell. The agents consist of derivatives of antimycins that bind to anti-apoptotic Bcl-2 family member proteins. These agents preferentially induce apoptosis in cells that over-express these proteins and typically exhibit reduced binding affinity for cytochrome B. The pharmaceutical applications of these agents include treating apoptosis-associated diseases, such as neoplasia and drug resistance.

Career Highlights

Hockenberry is affiliated with the Fred Hutchinson Cancer Center, where he continues to advance research in cancer treatment and cellular apoptosis. His innovative approaches have the potential to impact therapeutic strategies significantly.

Collaborations

Some of his notable coworkers include Julian Simon and Shie-Pon Tzung. Their collaborative efforts contribute to the ongoing research and development in the field of cancer biology.

Conclusion

David M Hockenberry's work in apoptosis modulation represents a significant advancement in cancer research. His innovative patent and contributions to the Fred Hutchinson Cancer Center highlight his commitment to improving therapeutic outcomes for patients.